[1]Global initiative for chronic obstructuive pulmonary disease(GOLD).Global Strategy for diagnosis，Management Prevention of COPD[EB/OL].(2017) [2023-01-10].https：//goldcopd.org/wp-content/uploads/2017/02/wms-GOLD-2017-FINAL.pdf. [2]Global initiative for chronic obstructuive pulmonary disease(GOLD).Global Strategy for diagnosis，Management Prevention of COPD[EB/OL].(2018) [2023-01-10].https：//goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf. [3]Global initiative for chronic obstructuive pulmonary disease(GOLD).Global Strategy for diagnosis，Management Prevention of COPD[EB/OL].(2019)[2023-01-10].https：//goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf [4]GOLD initiative for chronic obstructuive pulmonary disease(GOLD).Global Strategy for diagnosis，Management Prevention of COPD[EB/OL].(2020) [2023-01-10].https：//goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf. [5]Global initiative for chronic obstructuive pulmonary disease(GOLD).Global Strategy fordiagnosis，Management Prevention of COPD[EB/OL].(2021) [2023-01-10].https：//goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. [6]Global initiative for chronic obstructuive pulmonary disease(GOLD).Global Strategy for diagnosis，Management Prevention of COPD[EB/OL].(2022) [2023-01-10].https：//goldcopd.org/wp-content/uploads/2021/12/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf [7]Global initiative for chronic obstructuive pulmonary disease(GOLD).Global Strategy for diagnosis，Management Prevention of COPD[EB/OL].(2023) [2023-01-10].https：//goldcopd.org/wp-content/uploads/2022/12/GOLD-2023-ver-1.1-2Dec2022_WMV.pdf [8]赵宁宁，周玉明.保留比值受损肺功能人群研究进展[J].中华结核和呼吸杂志，2022，45（10）：1046-1050. [9]Wan ES，Castaldi PJ，Cho MH， et al. Epidemiology，genetics， and subtyping of preserved ratio impaired spirometry(PRISm) in COP Gene[J].Respir Res， 2014，15(1)：89. [10]Wan ES， Hokanson JE， Regan EA， et al. Significant spirometric transitions and preserved ratio impaired spirometry among ever smokers[J].Chest，2022， 161(3)：651-661. [11]Wijnant SRA，de Roos E，Kavousi M，et al. Trajectory and mortality of preserved ratio impaired spirometry： the rotterdam study [J].Eur RespirJ，2020，55(1)： 1901217. [12]Wan E S，Fortis S，Regan E A，et al. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPDGene study [J]. Am JrRespir Crit Care Med， 2018， 198(11)： 1397-1405. [13]Keener A.Redefining the diagnostic criteria for COPD[J]. Nature，2020，581(7807)：S4-S6. [14]周德训，魏敬安，陈清，等.肺功能非特异性表现的特点与临床意义[J].中华结核和呼吸杂志，2013，36（11)：821-824. [15]崔佳，许小毛，张洪胜，等.肺通气功能非特异性表现的分布及特点初探[J].中华结核和呼吸杂志，2016，39（3）：193-197. [16]黄永康，张文宇，黄建安.靶肺去神经疗法在慢性阻塞性肺疾病中的应用进展[J].中国呼吸与危重监护杂志，2021，20(21)：821-823. [17]何权瀛.对于将切断迷走神经用于治疗慢性阻塞性肺疾病的不同意见[J].中国呼吸与危重监护杂志，2022，21(7)：457-458. [18]张梦，魏智民，崔华，等. 北京地区4960例慢性阻塞性肺疾病住院患者合并卒中情况的多中心临床调查[J].解放军医学院学报，2013，(6)：562-565. [19]Pan Americna Health Organization/world Health Organization.Global tuberculosis report 2021[EB/OL].(2021-10-24)[2023-02-01].https：//www.who.int/publications/i/item/9789240037021 [20]Keshishian A，Xie L，Dembek C，et al.Reduction in hospital readmission rates among medicare beneficiaries with chronic obstructive pulmonary disease：areal-word outcomes study of nebulized bronchodilators[J].Clinical Therapeutics， 2019， 41(11)：2283-2296. [21]Lahousse L，Verhamme KM，Stricker BH，et al.Cardiac effects of current treatments of chronic obstructive pulmonary disease[J].Lancet Respir Med，2016，4(2)：149-164.
